These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9382371)

  • 1. Interferon-alpha for chronic hepatitis C: reducing the uncertainties.
    Koff RS
    Ann Intern Med; 1997 Nov; 127(10):918-20. PubMed ID: 9382371
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of interferon alfa 2b and ribavirin in the treatment of chronic hepatitis C.
    Kim WR; Poterucha JJ; Gross JB
    Hepatology; 2000 Mar; 31(3):807-8. PubMed ID: 10722315
    [No Abstract]   [Full Text] [Related]  

  • 3. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.
    Bennett WG; Inoue Y; Beck JR; Wong JB; Pauker SG; Davis GL
    Ann Intern Med; 1997 Nov; 127(10):855-65. PubMed ID: 9382363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
    Arguedas M
    Pharmacoeconomics; 2004; 22(7):477-8; author reply 478-9. PubMed ID: 15137884
    [No Abstract]   [Full Text] [Related]  

  • 5. Hepatitis C therapy: is it really worth it?
    Johanson JF
    Am J Gastroenterol; 1999 May; 94(5):1412-3. PubMed ID: 10235231
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost-effectiveness of treatment of chronic hepatitis B with interferon-alpha.
    Babu S
    Natl Med J India; 2003; 16(3):175; author reply 175-6. PubMed ID: 12929872
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-effectiveness of treatment of chronic hepatitis B with interferon-alpha.
    Desai HG
    Natl Med J India; 2003; 16(3):175; author reply 175-6. PubMed ID: 12929870
    [No Abstract]   [Full Text] [Related]  

  • 8. [Medico-economic assessment of the therapeutic management of patients with hepatitis C].
    Loubière S; Rotily M; Moatti JP
    Gastroenterol Clin Biol; 2000 Nov; 24(11):1047-51. PubMed ID: 11139674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6.
    Kapol N; Lochid-Amnuay S; Teerawattananon Y
    BMC Gastroenterol; 2016 Aug; 16(1):91. PubMed ID: 27492396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of treatment of chronic hepatitis B with interferon-alpha.
    Nagral A
    Natl Med J India; 2003; 16(3):175; author reply 175-6. PubMed ID: 12929871
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-utility analysis of different peg-interferon alpha-2b plus ribavirin treatment strategies as initial therapy for naïve Chinese patients with chronic hepatitis C.
    Lin WA; Tarn YH; Tang SL
    Aliment Pharmacol Ther; 2006 Nov; 24(10):1483-93. PubMed ID: 17081165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
    Wong JB; Poynard T; Ling MH; Albrecht JK; Pauker SG
    Am J Gastroenterol; 2000 Jun; 95(6):1524-30. PubMed ID: 10894590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Does combination therapy of chronic viral hepatitis C with interferon-alpha and ribavirin approach financial limits?].
    Steimann RU; Bode JC
    Versicherungsmedizin; 2000 Mar; 52(1):24-7. PubMed ID: 10718088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.
    Sullivan SD; Craxi A; Alberti A; Giuliani G; De Carli C; Wintfeld N; Patel KK; Green J
    Pharmacoeconomics; 2004; 22(4):257-65. PubMed ID: 14974875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A health economic model to assess the long term effects and cost-effectiveness of PEG IFN alpha-2a in hepatitis C virus infected patients.
    Annemans L; Warie H; Nechelput M; Peraux B
    Acta Gastroenterol Belg; 2004; 67(1):1-8. PubMed ID: 15149079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Minimization of endogenous intoxication syndrome by individual choice of drugs for therapy of chronic hepatitis].
    Vasil'eva DK; Goriacheva LG; Kotiv MIa; Alekseeva LA; Romantsov MG; Bessonova TV
    Antibiot Khimioter; 2011; 56(3-4):46-50. PubMed ID: 21913409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of chronic hepatitis C treatment by interferon-ribavirin combination therapy in Belgium.
    Delwaide J
    Acta Gastroenterol Belg; 2002; 65(4):233-6. PubMed ID: 12619432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical guidelines on the management of hepatitis C.
    Booth JC; O'Grady J; Neuberger J;
    Gut; 2001 Jul; 49 Suppl 1(Suppl 1):I1-21. PubMed ID: 11413125
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical benefits and cost-effectiveness of 17-year treatment with low-dose interferon-alpha 2b in a patient with chronic hepatitis C: a case report.
    Kawaguchi T; Sumie S; Itou M; Taniguchi E; Matoba T; Sata M
    Dig Dis Sci; 2009 Mar; 54(3):690-4. PubMed ID: 18661237
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost effectiveness of hepatitis C treatments: Need for a comprehensive evaluation.
    DeNardo Z; Choi M; Stiller M; Buechel D
    Kaohsiung J Med Sci; 2017 Nov; 33(11):584-585. PubMed ID: 29050677
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.